Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure's stock rockets into record territory after upbeat DMC review of lung cancer treatment trial
08:34am, Tuesday, 13'th Apr 2021
Shares of Novocure Ltd. skyrocketed 80.7% toward a record high in premarket trading Tuesday, after the tumor treatment company said an independent data monitoring committee (DMC) said the interim anal
NVCR Stock: Over 85% Increase Pre-Market Explanation
08:25am, Tuesday, 13'th Apr 2021
The stock price of NovoCure Limited (Nasdaq: NVCR) increased by over 80% pre-market. This is why it happened.
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
07:30am, Tuesday, 13'th Apr 2021
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #lcsm--Novocure announced an update on its phase 3 pivotal LUNAR trial of TTFields in stage 4 non-small cell lung cancer following platinum failure.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the AACR Annual Meeting 2021.
NovoCure: An Underfollowed Gem
08:14am, Wednesday, 07'th Apr 2021
NovoCure invented a new type of cancer treatment based on TTF (tumor treating fields). They use electricity to disrupt the division of cancer cells. The company is working to expand use cases via FDA
Novocure to Report First Quarter 2021 Financial Results
06:00am, Thursday, 01'st Apr 2021
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the first quarter 2021 on April 29, 2021, before the U.S. financial markets open.
Why NovoCure Stock Sank Today
03:32pm, Thursday, 25'th Feb 2021
The company announced delays of several clinical studies, with one analyst also predicting slower growth ahead.
NovoCure Limited (NVCR) CEO Asaf Danziger on Q4 2020 Results - Earnings Call Transcript
02:43pm, Thursday, 25'th Feb 2021
NovoCure Limited (NVCR) CEO Asaf Danziger on Q4 2020 Results - Earnings Call Transcript
NovoCure (NVCR) Q4 Earnings and Revenues Miss Estimates
08:22am, Thursday, 25'th Feb 2021
NovoCure (NVCR) delivered earnings and revenue surprises of -69.23% and -0.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
06:00am, Thursday, 25'th Feb 2021
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure today reported financial results for the quarter and full year ended December 31, 2020, and provided a company update.
Why Earnings Season Could Be Great for NovoCure (NVCR)
09:06am, Wednesday, 24'th Feb 2021
NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 Readout
03:40am, Tuesday, 09'th Feb 2021
Delcath Systems develops drug/device combos to treat liver cancers. The company's stock is underappreciated due to past clinical failures and a de-listing despite promising clinical data.
Investors Take Note: This Biotech Stock Has Multiple Readouts in 2021
09:45am, Sunday, 24'th Jan 2021
A new paradigm in cancer treatment is developing
Novocure Ltd.: A Shockingly Good Potential Ten Bagger
11:26am, Thursday, 21'st Jan 2021
Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy.
Are Options Traders Betting on a Big Move in NovoCure (NVCR) Stock?
09:47am, Friday, 15'th Jan 2021
Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.
